17/18 January 2007 Wiener Neustadt - Czelo
17/18 January 2007 Wiener Neustadt - Czelo 17/18 January 2007 Wiener Neustadt - Czelo
INTELLECTUAL PROPERTY RIGHTS (IPR): MARKET APPLICATIONS: TYPE OF COLLABORATION SOUGH search for applicability PARTNER PROFILE: research&development partners in industry 3. Profile: Expertise: Transfer of basic research to application DESCRIPTION: functionalization of magnetic hybrids/composites for sensoric applications INNOVATIVE ASPECTS: novel high magnetic field sensors MAIN ADVANTADGES / BENEFITS: temperature independent TECHNICAL SPECIFICATIONS: CURRENT STAGE OF DEVE
Institute of Virology and Biomedicine (AUSTRIANOVA BIOMANUFACTURING) Address Veterinärplatz 1 Austria 0 - Vienna Phone / Fax 0043 1 25077 2336 / 0043 1 25077 2390 www http://www.vu-wien.ac.at/i123/vironeu062005/english/index.htm Size 51-250 Organisation Type University Contact Person Name Dr John Dangerfield Position Group Leader Email john.dangerfield@vu-wien.ac.at Type of co-operation (Offered, Requested) Areas of activity Licence agreement Technical Co-operation (R&D) Boths Joint research project Boths Joint-venture agreement Manufacturing agreement Commercial agreement Financial agreement Short description of company THE RESEARCH INSTITUTE OF VIROLOGY AND BIOMEDICINE AND AUSTRIANOVA BIOMANUFACTURING AG THE RESEARCH INSTITUTE OF VIROLOGY AND BIOMEDICINE • Materials Technology • Medicine, Human Health • Biology / Biotechnology • The Institute With around 35 scientific staff, the main basic and developmental research focuses are with murine leukaemia, human and simian immunodeficiency, mouse mammary tumour and Rous sarcoma viruses. Virology has recently broadened its research spectrum into the area of bionanotechnology. Close collaborations with industry and other partners have allowed academic programmes designed to convert viruses into powerful vehicles for delivering therapeutic genes to be accelerated with the aim of entering clinical trials. Technology and Research and Development State-of-the-art replication competent retroviral vectors now allow up to 100% therapeutic gene transduction into animal tumour models. Despite this, medical applications are still limited due to the inability of being able to target vectors to the tumour site. To overcome this, work is currently underway to controllably bridge the bio – mineral interface by linking retroviral vectors with magnetic nanoparticles and organic/inorganic nano-electro-mechanical devices (NEMS) to enable in vivo targeting of vectors. For more detailed information see our website: http://www.vu-wien.ac.at/i123/vironeu062005/english/index.htm AUSTRIANOVA BIOMANUFACTURING The company AUSTRIANOVA BIOMANUFACTURING AG ranks among the leading Austrian biotechnology companies together with Intercell and Igeneon. Its offices and laboratories are located at the University of Veterinary Medicine in Vienna, where it was founded in 2001 as the first university spin off. AUSTRIANOVA’s lead-product, NovaCaps®, is used for targeted treatment of pancreatic carcinoma. The product consists of a genetically modified cell line (allogeneic), which is able to activate a prodrug directly at the site of the tumour. The product can be used “off- the shelf” for all patients and mediates highly specific tumour growth
- Page 1: • Electronics, Microelectronics
- Page 4 and 5: Organisation Index Institute of Phy
- Page 6 and 7: Organisation Index TECHNICAL UNIVER
- Page 8 and 9: Organisation Index Faculty of Mater
- Page 10 and 11: 1. Profile: RTD: High sensitive wea
- Page 12 and 13: New applications or new products re
- Page 14 and 15: AMAG rolling GmbH Address Postfach
- Page 16 and 17: Attophotonics Biosciences GmbH Addr
- Page 18 and 19: austriamicrosystems Address Tobelba
- Page 20 and 21: Austrian Researc Centers GmbH - ARC
- Page 22 and 23: Austrian Research Centers GmbH - AR
- Page 24 and 25: D. Swarovski & Co. Address Swarovsk
- Page 26 and 27: FFG - EIP - Austrian EUREKA Office
- Page 28 and 29: FFG Austrian Research Promotion Age
- Page 30 and 31: FFG Austrian Research Promotion Age
- Page 32 and 33: Happy Plating GmbH Address Leobersd
- Page 34 and 35: Institute of Materials Science and
- Page 38 and 39: inhibition with minimal drug induce
- Page 40 and 41: Integrated Microsystems Austria Gmb
- Page 42 and 43: Joanneum Research GmbH Address Stey
- Page 44 and 45: Joanneum Research, Insitute of Nano
- Page 46 and 47: Kunststoff-Cluster, Clusterland Obe
- Page 48 and 49: M.Kaindl Flooring Address Kaindlstr
- Page 50 and 51: CURRENT STAGE OF DEVELOPMEN plannin
- Page 52 and 53: MAGNIFIN Magnesiaprodukte GmbH & Co
- Page 54 and 55: Montanuniversität - Nanonet Styria
- Page 56 and 57: Polymer Competence Center Leoben Gm
- Page 58 and 59: 1. Profile: Expertise: Nanoimprint
- Page 60 and 61: Psisys Ing.C.Vacariu Address Suchen
- Page 62 and 63: state-of-the-art characterization m
- Page 64 and 65: 1. Profile: Reques Electrochemical
- Page 66 and 67: Sony DADC Austria AG Address Sonyst
- Page 68 and 69: + Strategieentwicklung + Innovation
- Page 70 and 71: Technology Consulting Centre TBZM A
- Page 72 and 73: TU Wien and Austrian Center of Comp
- Page 74 and 75: TU Wien- institute for solid state
- Page 76 and 77: University of Linz Address Altenber
- Page 78 and 79: University of Vienna, Department of
- Page 80 and 81: Vienna University of Technology, In
- Page 82 and 83: Zentrum für Mikro- und Nanostruktu
- Page 84 and 85: INTELLECTUAL PROPERTY RIGHTS (IPR):
Institute of Virology and Biomedicine (AUSTRIANOVA BIOMANUFACTURING)<br />
Address Veterinärplatz 1 Austria<br />
0 - Vienna<br />
Phone / Fax 0043 1 25077 2336 / 0043 1 25077 2390<br />
www http://www.vu-wien.ac.at/i123/vironeu062005/english/index.htm<br />
Size 51-250<br />
Organisation Type University<br />
Contact Person<br />
Name Dr John Dangerfield<br />
Position Group Leader<br />
Email john.dangerfield@vu-wien.ac.at<br />
Type of co-operation (Offered, Requested) Areas of activity<br />
Licence agreement<br />
Technical Co-operation (R&D) Boths<br />
Joint research project Boths<br />
Joint-venture agreement<br />
Manufacturing agreement<br />
Commercial agreement<br />
Financial agreement<br />
Short description of company<br />
THE RESEARCH INSTITUTE OF VIROLOGY AND BIOMEDICINE<br />
AND<br />
AUSTRIANOVA BIOMANUFACTURING AG<br />
THE RESEARCH INSTITUTE OF VIROLOGY AND BIOMEDICINE<br />
• Materials Technology<br />
• Medicine, Human Health<br />
• Biology / Biotechnology<br />
•<br />
The Institute<br />
With around 35 scientific staff, the main basic and developmental research focuses are with murine leukaemia,<br />
human and simian immunodeficiency, mouse mammary tumour and Rous sarcoma viruses. Virology has recently<br />
broadened its research spectrum into the area of bionanotechnology. Close collaborations with industry and other<br />
partners have allowed academic programmes designed to convert viruses into powerful vehicles for delivering<br />
therapeutic genes to be accelerated with the aim of entering clinical trials.<br />
Technology and Research and Development<br />
State-of-the-art replication competent retroviral vectors now allow up to 100% therapeutic gene transduction into<br />
animal tumour models. Despite this, medical applications are still limited due to the inability of being able to target<br />
vectors to the tumour site. To overcome this, work is currently underway to controllably bridge the bio – mineral<br />
interface by linking retroviral vectors with magnetic nanoparticles and organic/inorganic nano-electro-mechanical<br />
devices (NEMS) to enable in vivo targeting of vectors.<br />
For more detailed information see our website:<br />
http://www.vu-wien.ac.at/i123/vironeu062005/english/index.htm<br />
AUSTRIANOVA BIOMANUFACTURING<br />
The company<br />
AUSTRIANOVA BIOMANUFACTURING AG ranks among the leading Austrian biotechnology companies<br />
together with Intercell and Igeneon. Its offices and laboratories are located at the University of Veterinary<br />
Medicine in Vienna, where it was founded in 2001 as the first university spin off.<br />
AUSTRIANOVA’s lead-product, NovaCaps®, is used for targeted treatment of pancreatic carcinoma. The product<br />
consists of a genetically modified cell line (allogeneic), which is able to activate a prodrug directly at the site of the<br />
tumour. The product can be used “off- the shelf” for all patients and mediates highly specific tumour growth
Change language